Medicaid coverage for GLP-1 weight-loss drugs stalls, only Indiana signs on

President Trump pledged to broaden Medicaid access to costly GLP-1 obesity medications by letting states negotiate prices directly with manufacturers.

The rollout depended on state participation, but to date only Indiana has signed on to the program.

Consequently, most low‑income patients across the country remain without Medicaid coverage for these weight‑loss drugs, underscoring the difficulty of translating federal pricing promises into widespread access.